Fulgent Genetics, Inc.

DB:7F0 Stock Report

Market Cap: €524.9m

Fulgent Genetics Valuation

Is 7F0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 7F0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 7F0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 7F0's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 7F0?

Key metric: As 7F0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 7F0. This is calculated by dividing 7F0's market cap by their current revenue.
What is 7F0's PS Ratio?
PS Ratio2x
SalesUS$277.76m
Market CapUS$546.59m

Price to Sales Ratio vs Peers

How does 7F0's PS Ratio compare to its peers?

The above table shows the PS ratio for 7F0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SYAB SYNLAB
1x4.4%€2.5b
V3V VITA 34
0.9x3.1%€72.5m
FRE Fresenius SE KGaA
0.8x3.6%€18.8b
FME Fresenius Medical Care
0.6x3.8%€12.4b
7F0 Fulgent Genetics
2x12.7%€546.6m

Price-To-Sales vs Peers: 7F0 is expensive based on its Price-To-Sales Ratio (2x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does 7F0's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.67m
No more companies available in this PS range
7F0 2.0xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 7F0 is expensive based on its Price-To-Sales Ratio (2x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 7F0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

7F0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: 7F0 is expensive based on its Price-To-Sales Ratio (2x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 7F0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€16.10
€24.72
+53.5%
12.5%€28.16€20.65n/a3
Nov ’25€19.70
€25.25
+28.2%
6.1%€27.38€23.73n/a3
Oct ’25€19.40
€25.25
+30.1%
6.1%€27.38€23.73n/a3
Sep ’25€20.80
€25.25
+21.4%
6.1%€27.38€23.73n/a3
Aug ’25€22.00
€24.77
+12.6%
8.8%€27.87€23.22n/a3
Jul ’25€18.10
€24.77
+36.9%
8.8%€27.87€23.22n/a3
Jun ’25€18.70
€24.77
+32.5%
8.8%€27.87€23.22n/a3
May ’25€19.10
€24.47
+28.1%
8.8%€27.53€22.94n/a3
Apr ’25€19.74
€24.47
+24.0%
8.8%€27.53€22.94n/a3
Mar ’25€20.70
€25.60
+23.7%
7.4%€27.76€23.13n/a3
Feb ’25€22.60
€30.25
+33.9%
10.1%€32.41€25.93n/a3
Jan ’25€26.70
€30.25
+13.3%
10.1%€32.41€25.93n/a3
Dec ’24€25.10
€29.38
+17.0%
11.1%€32.64€26.11n/a2
Nov ’24€22.35
€34.56
+54.6%
23.3%€42.61€26.51€19.702
Oct ’24€25.15
€38.37
+52.6%
9.8%€42.12€34.63€19.402
Sep ’24€30.00
€40.15
+33.8%
12.2%€45.62€33.76€20.803
Aug ’24€34.95
€38.48
+10.1%
8.9%€40.90€33.63€22.003
Jul ’24€34.30
€38.48
+12.2%
8.9%€40.90€33.63€18.103
Jun ’24€37.10
€38.48
+3.7%
8.9%€40.90€33.63€18.703
May ’24€26.35
€38.83
+47.4%
11.3%€41.94€32.62€19.103
Apr ’24€26.98
€38.83
+44.0%
11.3%€41.94€32.62€19.743
Mar ’24€30.43
€40.64
+33.6%
5.4%€42.21€37.52€20.703
Feb ’24€30.70
€42.63
+38.9%
9.1%€47.37€37.90€22.603
Jan ’24€27.84
€42.63
+53.2%
9.1%€47.37€37.90€26.703
Dec ’23€34.34
€51.66
+50.4%
15.9%€62.97€43.59€25.103
Nov ’23€39.48
€67.66
+71.4%
3.7%€70.16€65.15€22.352

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%